Healthcare News

MARKHAM, Ontario, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a...

Quoin Pharmaceuticals reports Q2 2026 results, FDA conditional approval of QYLEKI™, and clearance of the first-ever IND for Peeling Skin Syndrome.

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in...

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026Clene announces survival and functional benefit in...

NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...

COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a...

   - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion...

Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completedRezatapopt NDA submission for...

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3...

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has...